Name (Synonyms) | Correlation | |
---|---|---|
drug1280 | Ivermectin Pill Wiki | 1.00 |
drug613 | Combined ART/hydroxychloroquine Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D058345 | Asymptomatic Infections NIH | 1.00 |
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Rationale: Infection with severe acute respiratory syndrome coronavirus (SARS-CoV) 2 could result in endothelial dysfunction with increased risk of arterial thrombotic events by downregulating the expression of angiotensin converting enzyme 2 (ACE2). Endothelial function can be easily and non-invasively determined by carotid artery reactivity (CAR) testing. Objective: To investigate the predictive value of endothelial dysfunction, measured by carotid artery reactivity testing, for 1-year cardiovascular events in patients with past COVID-19 infection. Study design: A prospective observational longitudinal cohort study. Study population: Patients recovered from confirmed infection with SARS-CoV2. Main study parameters/endpoints: macrovascular endothelial function measured by carotid artery reactivity testing.
Description: Change in endothelial dysfunction as determined by CAR test.
Measure: Endothelial dysfunction Time: CAR will be measures between 6 and 20 weeks and 1 year after recovery from COVID-19.Description: MACE include non-fatal myocardial infarction, non-fatal ischemic stroke, acute limb ischemia, need for revascularization, amputation and cardiovascular death.
Measure: Major adverse cardiovascular events (MACE) Time: 1 year